The US Food and Drug Administration’s (FDA’s) new pathway for gene therapies could be “groundbreaking” if applied broadly, though the extent of its scope remains unclear. In a New England Journal of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback